Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Orion, Webcast, Q4'25

By Inderes2/12/2026, 12:00 PM
Orion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tuukka Herman
00:01 - 01:05

Good afternoon and welcome to Orion Corporation's Full-Year 2025 Results webcast and conference call. My name is Tuukka Herman and I am the Head of IR here at Orion. In a few moments, our CEO, Lisa Hurme, will present the results for the full year and Q4 last year, after which you will have the possibility to ask questions from Lisa and also from our CFO, René Lindell. We will be first taking questions through the conference call lines, and after that we will turn to the webcast. So through the webcast, you have the possibility to type in your questions through the chat function of the webcast. And just before I let Lisa take over, I'd like to draw your attention to this usual disclaimer regarding future forward-looking statements. And with this short note, it's my pleasure to invite Lisa to the podium. Liza, please.

Lisa Hurme
01:07 - 16:13

This was an all-time high year for Orion, for both net sales and operating profit. And welcome on my behalf as well. I'll start with Q4 and some highlights during the last three months of last year. It's my pleasure to say that all our business divisions had a strong quarter and performed extremely well. Also, we received a 180 million sales milestone from Bayer related to Nubeqa, and we were able to proceed with our clinical pipeline by initiating a Phase 2 program with ODM-212, a molecule in our oncology pipeline, while our partner Tenax in the United States also initiated a Phase 3 trial called LEVEL-2 with levosimendan for pulmonary hypertension. And Q4. Highlights. Compared to the previous year, the base business during Q4 grew 18.5% (and 60% including the previously mentioned milestone), while operating profit grew 59% (and 254% including the milestone), bringing us to a 47% operating profit margin in Q4; operating cash flow per share was slightly lower than the previous year, mainly due to the timing of royalty payments from Bayer. The net sales bridge is almost masked by Nubeqa and Innovative Medicines, as it includes the 180 million milestone, but it doesn't shadow the extremely, extremely good performance of other divisions, Branded Generics and Animal Health. Of course, the divisions are smaller, so the growth in euros is also smaller. And this all resulted in €695 million in net sales during Q4. Regarding the operating profit. We, of course, see the 180 million, but a very good development on our royalties, close to 50 million, and also sales volumes brought us €28 million. Price development costs and product mix put us slightly down by 12 million, and the effect of exchange rate on gross margin was 4.1 million, and other operating costs and fixed costs were also well handled. So no, nothing specific there. And so our Q4 operating profit was 328 million. And now I move to 2025. This was an all-time high year for Orion Pharma, both with net sales and operating profit. And I want to take the opportunity here today to thank all my colleagues all around the world in Orion Pharma for this achievement. Overall, this involved all business divisions, R&D, and operations. You couldn't achieve anything like this without a very, very good collaboration in the company. So, in addition to euros, we also had numerous positive developments in R&D, including ARASTEP approvals both in Europe and the US. Several new license and collaboration agreements were established, including license agreements for early-stage technology platforms in our innovative medicines and oncology, but also acquiring and in-licensing product rights for both branded products and generics. Also, MSD, our other significant partner, expanded the Opevesostat development to women's cancers, which is wonderful news both for women suffering from these cancers and for taking all the possible opportunities of this molecular mechanism of action. The Board of Directors of Orion Corporation is proposing a dividend of €1.8 per share, and this is proposed to be paid in two installments. For the full year, our base business achieved 21% growth, with total growth reaching 22.5% including milestones; operating profit for the base business increased by 58% (or 59% if rounded), and by 52% including milestones, which impacts the full-year operating profit margin. This brings us to 33.4% compared to the previous year's 27%. And of course, this is mainly, or partly, due to the milestone that we received. Operating cash flow was slightly better than in 2024, driven mainly by sales performance, as the milestone will be visible in the cash flow only this year. And now I move to the divisions. For Innovative Medicines, net sales are primarily from Nubeqa, comprising both royalties and product sales. The dark part here describes the sales and royalties, where the growth was close to 38%. Of course, with the milestone also included, this brings us to 152% growth. And then, for the full year, the growth was 60% for the base business and 55% with the milestone. And then there is the picture that we always want to have here to remind you of the very back-end loaded character of this business due to the tiered royalties from Bayer, and we can see it extremely well here in Q4 2025, where the royalties jump up significantly from the previous quarter. The product deliveries and product sales between Q3 and Q4 last year remained at a similar level. Branded Products continued. In Q4, the double-digit growth was 11%, and the full year growth was close to 10%. For the respiratory portfolio. The growth comes from the budesonide formoterol combination product for the CNS. It comes from Stalevo or the Entacapone product family for Parkinson's disease, and especially retaining the rights in Japan back to Orion Pharma, but also from some new products that we've been launching in Europe and then a significant growth of our women's Health portfolio. Generics and Consumer Health achieved strong results last year. 5.7% growth during Q4 is above all averages in this business, and 4.6% for the full year as well. And this is a result of a lot of activities. We've done more launches than ever in our current territories. We've had some bigger launches this year for products whose patents have ended. And this comes also from all of our regions. Animal Health Q4 was more subdued compared to the previous quarters, with only 1% growth. And this is mainly when you see these types of changes on a quarterly basis. In Animal Health, it's usually the delivery timing of products to our partners. However, it didn't have a big effect on the full year sales, where the growth is close to 10%. And in a similar way to generics, the growth truly comes from a broad geographic region globally, as well as from a broad portfolio covering both livestock and companion animal businesses. This is a nice list of our ten biggest products. Almost all products are growing, some even with very healthy two-digit numbers, while others are more or less at par, like Animal Health, Dexdomitor, and Burana. It is worth noting that the Divina series. The Women's Health portfolio has now climbed to be the number four, so it has actually now climbed past the Animal Health sedative portfolio. And this is a very natural order of products here, with the innovative product Nubeqa as the first and fastest-growing product. And then the three main branded products follow. And then we have the biggest generic products represented here. Simdax. Unfortunately, of course, Fareston's decline is again a matter of delivery timing. I think the big message in this slide is that, to my recollection, this is the first year when Innovative Medicines is our biggest division. So this is clearly a kind of a landmark event for Orion. Generics still generate almost 30% of our net sales, and Branded Products contribute 17%. And the two other divisions, Animal Health and Fermion, are significantly smaller ones. Regarding our key clinical development. Pipeline. I already mentioned that we've started Phase 2 for ODM-212 in two different indications, including mesothelioma, both of which are rare oncology indications. We were able to start this study already at the end of last year, and are aiming to start a study with the combination of this molecule with some current oncology treatments during the first part of this year. And also you can see here now two studies for Levosimendan, also the LEVEL-2. And this is a very nice slide on sustainability. This time about diversity. Orion has been ranked as number three in the Nordic Business Diversity Index, which means that if you look at the numbers here on this slide, you can see how men and women are represented. What is the share of men and women on different levels of the organization? You can look at the board of directors, where almost 40% of members are women. Almost 45% of the members are women. And if you look at the whole personnel in Orion Pharma, almost 56% of the personnel are women. And there is a lot of other information here of which we are very, very proud. One that I can mention is the accomplishment of the Code of Conduct Agreements with our suppliers, which is 98%. We provided our outlook for 2026 already on January 14th, and it holds. So we've stated that our net sales range for this year is 1.9 billion. 1.9 billion to 2.1 billion, and our operating profit range is 550 million to 750 million. And here are our upcoming events and our general meeting. Annual General Meeting will be held on 24th of March. I thank you for your attention at this point and we are ready for your questions.

Tuukka Herman
16:14 - 16:33

Thank you Lisa. So now we are opening the floor for Q&A. Just as a reminder to the webcast viewers that you can type in your question using the chat function of the webcast. But first, let's turn to the conference call lines, and I'd like to hand over to the operator at this point.

Operator
16:37 - 16:59

If you wish to ask a question, please dial Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Sean Hammer from Jefferies. Please go ahead.

Sean Hammer
17:03 - 17:25

Hey, thank you so much for taking my questions. Just two from me, please. We can take them one at a time. So, firstly, could you just outline how you expect OpEx to develop over the course of this year, as in compared to 2025? What sort of levels of SG&A and R&D are we expecting? Are we looking at as a percentage of the top line? My first question.

Lisa Hurme
17:27 - 17:29

I'll take this question.

René Lindell
17:29 - 18:04

Of course, we are not giving a detailed guidance on opex levels within the guidance, but we have been stating that we are initiating more activities in the clinical pipeline. We have ODM-212 that entered Phase 2 and are planning to expand. So R&D OpEx. You can imagine that we are planning to increase during the year. And then, when it comes to sales and marketing, we have also been investing more in those efforts across our countries, especially in the Branded Products division. So also there is some growth during 2026.

Sean Hammer
18:07 - 18:30

Are you able to provide us with some further guidance as to your agreement with Bayer and what that looks like following the patent expiry? I thank you for your attention at this point, and we are ready for your questions. And just my second question, please. Are you able to provide us with some further guidance as to your agreement with Bayer and what that looks like following the patent expiration? Expiries. I think you previously stated low level percentage royalties after the patent expires. But what is the low level and will that eventually go to zero after 2035?

Lisa Hurme
18:33 - 18:55

I think exactly as you pointed out, it's a low single-digit royalty that we can receive from Bayer after the product has become generic. And maybe. Did you have something else in your mind regarding that? We can confirm that here, but yes.

Sean Hammer
18:55 - 19:03

As in, will it go to zero after 2035? I think that's when the patent expires in Europe, if I'm not mistaken.

Lisa Hurme
19:05 - 19:25

To my recollection, in a very general way, as these agreements are done, it's a region-by-region agreement that whenever patents expire, generic competition starts in a certain region. So then the new royalty rate kicks in.

Sean Hammer
19:27 - 19:29

But what is the low level, and will that eventually go to zero after 2035? Thank you so much for taking my questions.

Operator
19:34 - 19:41

The next question comes from Sami from Danske Bank markets. Please go ahead.

Sami
19:45 - 20:33

But what is the low level and will that eventually go to zero after 2035? Hi. I have a couple of questions. We'll also be taking this one by one. Starting from the outcome for last year. It was a great year, but you didn't actually exceed your own expectations around mid-2025, even though Nubeqa sales actually developed very strongly during the second half of the year. So why did we land at the guidance midpoint and not above it? My point is that Nubeqa probably reached some sort of blue sky scenario last year, but in which areas? That wasn't the case. So, was it related to other products not selling that well, or maybe costs? Becoming larger than anticipated?

René Lindell
20:34 - 21:28

Yeah. So if you look at the net sales, we landed pretty close to our upper range of our outlook. So that clearly was on the high side, not in the midpoint, then on the operating profit, we were quite close to the midpoint. However, there as well, we had a little bit more of an opex, but again, that we kind of expected, as I said, we had R&D investments last year that increased significantly year on year, and especially even if you consider a comparable without the write-downs in 24, you can see that actually the ongoing activity increased even more. So, in a way, you could say we really executed on the plan, both on the R&D side and also on the sales and marketing side. We went exactly as planned. So I think for us, we were quite at the mark.

Sami
21:31 - 21:49

And then going back to the cost outlook that was also discussed. And then going back to the cost outlook that was also discussed. The R&D cost increase will be significantly more material this year than the sales and marketing cost increase.

René Lindell
21:50 - 22:19

Not necessarily. So I think in both sides we are investing. So, of course, we'll have to see how the year goes. Sales and marketing, I think it's pretty clear what we have in the budget that it will increase, and R&D is also increasing. But again, it's less predictable. So that's why there is also a variety in the outlook range, where R&D expense plays a significant role.

Lisa Hurme
22:20 - 22:43

And to continue from that, we are really, as René already said, executing our plan. We were executing our plan for 2025, and we are executing our strategy, which is to invest more in R&D. And you can already see it in 25 if you compare 25 numbers to the 24. And that is expected to continue.

Sami
22:45 - 23:08

And maybe to add. And can you still open up a bit the factors that are driving sales and marketing cost increase this year? And maybe also you're planning to have a presence in the US market someday. When do you think those more material sales and marketing investments will happen?

René Lindell
23:10 - 23:43

I think that the largest factors would be in Branded Products and obviously Easyhaler as being the biggest product. That's where we had the most activities. So logically driving more sales there requires also activities in that regard. Establishing that platform in the USA, of course, that also plays a role, but it's still quite small in the big picture of things. But of course we are. We are steadily, step by step, undertaking activities there. But it's a very small scale. But it's all part of the total.

Tuukka Herman
23:45 - 23:46

And maybe to add.

Sami
23:46 - 23:46

And then.

Tuukka Herman
23:48 - 23:57

Of course, also the royalties which we are paying as Nubeqa grows. Of course, we are paying more and more royalties to Endo, and that is shown in the sales and marketing cost.

Lisa Hurme
23:58 - 24:04

Thank you for the reminder about that. So that's really gross sales for Nubeqa.

René Lindell
24:04 - 24:08

That drives a variable expense with Nubeqa's growth.

Sami
24:09 - 24:26

Yes. And then my final question would be on capital investments. You had quite an increase last year. You're guiding for similar level this year. Where are you investing at the moment?

René Lindell
24:27 - 24:55

If I single out the largest investments, those would be in Nubeqa production, especially in API production. And then secondly, last year we also had an Easyhaler. But of course, we are continuing our investments across all our divisions. So, as we are growing, we need more capacity for all the products that we are producing on our own. So, in a way, it grows also in line with the business. But naturally, one of the big things is really darolutamide.

Sami
24:58 - 25:00

The balance, or how? The balance or the how? I don't have any further questions.

Operator
25:04 - 25:10

The next question comes from Iris Thiemann from DNB Carnegie. Please go ahead.

Iris Thiemann
25:17 - 25:36

Hi. Thanks for your presentation. I have three questions, please. So, firstly, R&D costs were higher than I expected in Q4. Did those include any one-offs, for instance, related to ODM 105, which is my first question?

Lisa Hurme
25:37 - 27:11

Well, mainly the R&D costs. I don't recall that; maybe Renee knows the details, but I don't recall if they had any one-offs for ODM 105. But of course, the increase in R&D costs is fully in line with our strategy and plans. And as we have several chosen biologics candidates that we hope to bring to clinical development, at least one this year and another in 2027. The balance or the sequencing? The R&D costs are actually sequenced when you develop biologics. There are a lot more costs already before the clinical development when you need to have your final product, your final pharmaceutical product, and commercial batches validated before you enter your clinical studies. So I do fully understand it might be difficult to understand where we spend the money when you still see that there are not that many projects in the clinical phase? So those are actually quite expensive in the light of earlier pipeline molecules that we've had. And of course, we've been bringing ODM-212 into clinical phase and initiated the Phase 2 study last year. And that, of course, has also included kind of one-offs and payments for CROs. So I have nothing to do with 105 unless Renee says otherwise.

René Lindell
27:12 - 28:00

Maybe just on the dynamics of the R&D spend. Typically, at the end of the year, there are a bit more bills for external CROs. They tend to be back end loaded over the years. Oh, the 105. Yes, there were a few, I would say single-digit millions in terms of payments that we booked basically for things that are still being done to ramp down, and then, as you said, also starting up the new clinical trials, there were also upfront payments that came there. But all of these are probably typical, with some fluctuations. But the big message is that when comparing full year to full year, we expect a steady growth of R&D.

Sean Hammer
28:03 - 28:03

Okay.

Iris Thiemann
28:03 - 28:19

And still related to R&D costs. So is it fair to assume that your costs this year will be in your historical range of about 10 to 12% of sales?

René Lindell
28:20 - 28:41

I would not promise that history is the best predictor of the future. It will really depend on how the projects move forward. So we've been many years at 11%, but the target is to move further in the clinics. And that might also mean that we exceed the clinical or the historical ranges. But we'll have to see how the year goes.

Iris Thiemann
28:43 - 28:52

There are a lot more costs already before clinical development when you need to have your final product, your final pharmaceutical product, and commercial batches validated before you enter your clinical studies. And then secondly, what was the reason behind the flat Nubeqa product sales quarter over quarter in Q4?

Lisa Hurme
28:54 - 29:23

Well, there is a lot of fluctuation. Generally, of course, the deliveries have been growing as the sales have been growing. But as we've stated many times, so there are differences between quarters. It's a bit of the same thing as with other products to our partners, that it might be a timing of delivery between one day to another, and then it ends up in a different quarter or even a different year. Yes.

Iris Thiemann
29:27 - 29:39

Okay. And then my final question is related to R&D pipeline. So what is your expected pipeline news in the next 6 to 12 months?

Lisa Hurme
29:40 - 30:23

I think the next one will be the start of the ODM-212, in combination with some current oncology drugs that are used. As I said, we hope to start those studies before the summer, during the first half of this year. And from there on. During this year, we aim to bring one biologic product into the clinical stage and then going forward to 2027. There should be results. And now I'm looking at Tuka already from one of the Nubeqa studies. So are they. Both readouts are in 28.

Tuukka Herman
30:24 - 30:43

The ARASTEP study for the BCR is due to readout in 27. Then the DASL-HiCaP is due to readout in 28. So in the second half of 2026, our partner Tenax is expecting to read out the first LEVEL Phase 3 trial in the second half of this year.

Lisa Hurme
30:43 - 30:57

Exactly. So, this year's events are really starting the ODM-212 combination study, LEVEL study results, and also initiating biologics clinical development.

Iris Thiemann
30:59 - 31:04

And do you expect anything related to Opevesostat in the next 12 months?

Lisa Hurme
31:05 - 31:08

I think that's something that you would need to ask from MSD.

Iris Thiemann
31:11 - 31:12

So what is your expected pipeline news in the next 6 to 12 months? So what is your expected pipeline news in the next 6 to 12 months?

Operator
31:17 - 31:22

The next question comes from Alex Moore from Bank of America. I think that's something that you would need to ask from MSD.

Alex Moore
31:25 - 32:09

Hi. It's Alex Moore on for Charlie Hayward. Bank of America. Two more from you on Nubeqa. On the greater than 1 billion guidance on net sales, can you confirm your assumptions around expansion into early line settings? On the data for '27 and '28. And then secondly, just a clarifying question on the royalty post. Post LOE, you mentioned that the royalty rate drops to a very low rate after generic competition has started on a country by country basis; can you give a bit more color on timing? That is. Does this mean the royalty rate drops on the launch of the first generic competitor in a particular market, or is there more nuance there?

Lisa Hurme
32:11 - 32:22

May I repeat your first question? So did you ask whether the early-stage indications with Nubeqa are included in the 1 billion?

Alex Moore
32:23 - 32:24

Correct.

Lisa Hurme
32:24 - 33:07

That was your question. Yes. They are in a similar way as anything that Bayer is saying about Nubeqa. They include all the indications and the ongoing studies that need to be successful to reach what they are planning. And then your next question was regarding the royalty rate after the loss of exclusivity and how that would go. Usually the agreements are designed so that the royalty rate drops either when the first generic enters the market or the patent is expired. Region by region.

Alex Moore
33:10 - 33:11

May I repeat your first question? May I repeat your first question?

Tuukka Herman
33:16 - 33:41

May I repeat your first question? May I repeat your first question? We have now, for the time being, exhausted the questions. All the questions from the conference call line. Then we can turn to the webcast questions. We have a few of them here. Let's start with a few. One from Marty from OP markets. So the first one from Marty is what kind of reasons impacted on increased R&D and especially the sales and marketing costs in Q4.

René Lindell
33:43 - 34:13

I think we already discussed the R&D costs. So I think we already answered that. I will not repeat it. So, regarding sales and marketing, again, maybe repeating what Tomi also mentioned, royalties were a big part of that. And of course, the €180 million milestone was one big event in Q4, which also included royalties. But then the other piece involves added activities, as we have recruited more salespeople across our markets where we are seeing good momentum and growth, for example, for Easyhaler.

Tuukka Herman
34:15 - 34:33

Then we'll continue with the cost side. Hot topic today. So this is again from Marty. What should we think about sales and marketing costs especially for 2026? Will there be similar seasonality as in 25, or is the Q4 level the new normal, so to say?

René Lindell
34:34 - 35:07

I think there is some fluctuation between the quarters due to various factors. So I think it also might be risky to take one quarter and multiply by four, but rather look at the total year levels as we typically do. You get a more continuous picture of how that would develop. Yes, there is always some seasonality, and typically Q4, even in that space, can have some extra costs that are back-loaded, like in R&D. So I would also look at a broader picture of how the costs develop.

Tuukka Herman
35:09 - 35:22

Thanks, Renee. Then the final one from Marty is related to Fermion. Typically, Fermion sales have been decreasing due to increased Nubeqa production. So why did the external sales of Fermion increase during Q4?

Lisa Hurme
35:23 - 35:48

This is a good and nice question because let's remember that these sales, as was pointed out, are the external sales for other pharma companies. And we were clearly able to deliver before the year end more than we've been able to do earlier. So I think this is a result of good deliveries before the year-end.

Tuukka Herman
35:50 - 36:08

Thanks, Lisa. Then move on. This question comes from Victor Sudbury from Nordea Markets. So just wondered if you could provide any details on what you assume in the high end and in the low end of your guidance range to get a better feel for the risks and uncertainties going into 2026.

René Lindell
36:09 - 37:15

Yes, of course, I can't give you details within the range, but I think if we talk broadly about the range, the biggest factor, of course, for this year is Nubeqa, which is growing at the rate we're seeing; we expect it to do very strongly this year. It grows as its share of the total business. Naturally, that means also the range where Nubeqa lands and the impact on Orion is increasing. We mentioned already R&D opex. It is also increasing, but there is uncertainty over there as well regarding how projects move forward, how fast, and how the spend will be, plus other factors such as the US dollar to euro exchange rate. FX starts to impact more because a lot of the Nubeqa sales, of course, is in USA. So that is in there as well. Plus, the other divisions bring their normal variations as well. So it's the sum of all of these. And in the end, as we've typically state, when we look at the midpoint, that's kind of our base case where things move according to our plans.

Tuukka Herman
37:17 - 37:32

Thank you Renee. Now we have exhausted the questions from the webcast. And I can hear that there are no follow-ups on the conference call line. So at this point, I'll hand over to Lisa for any closing remarks.

Lisa Hurme
37:32 - 37:44

Thank you for your attention. And again, thank you to everybody for this excellent year 2025. We are heading towards another good year of 2026. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…